About this trial
The goal of this prospective observational study is to find out whether the protein vascular endothelial growth factor (VEGF) measured in blood and urine can predict which patients will develop acute kidney injury (AKI) after heart-type surgery that uses a heart-lung machine (cardiopulmonary bypass).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years
Elective cardiac surgery using cardiopulmonary bypass
Written informed consent
Disqualifiers
Pre-existing chronic kidney disease with an eGFR <20 ml/min/1,73m2
Usage of VEGF-inhibitors
Patients with pre-existing AKI within the last 30 days
Emergency surgery
Trial population
Adult patients undergoing elective cardiac surgery with use of cardiopulmonary bypass
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Association of vascular endothelial growth factor (VEGF) levels with postoperative acute kidney injury
Secondary outcomes
Difference in VEGF levels between patients with and without chronic kidney disease
Difference in VEGF levels between patients with transient and persistent acute kidney injury (AKI) after cardiac surgery
Comparison of VEGF levels between patients with transient AKI (resolving within 48 hours of onset) and persistent AKI (lasting more than 48 hours), among patients who develop AKI within the first 3 postoperative days following cardiac surgery.
Association of VEGF levels with length of ICU-stay
Association between perioperative VEGF levels and the duration of index intensive care unit (ICU) stay following cardiac surgery.
Association of VEGF levels with length of hospital stay
Association between perioperative VEGF levels and the duration of index hospital stay following cardiac surgery.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: